A fourth trastuzumab biosimilar has been approved by the US Food and Drug Administration (FDA). Pfizer's biosimilar version of trastuzumab-qyyp (Trazimera) gained approval on March 11. The principal phase 3 study tested Trazimera against the EU-licensed version of Herceptin®. The REFLECTIONS B327-02 study found no relevant differences in the clinical and safety outcomes for patients with … Continue reading Pfizer Receives Approval for Trazimera, the Fourth Trastuzumab Biosimilar →